MAPT and Alzheimer disease: Previous studies in our lab showed that KLC1 reduction in mice leads to altered localization and phosphorylation of Tau while KLC1 heterozygous animals also expressing a human APP transgene exhibit increased brain Aβ, two phenotypes associated with AD [11], [25], [26].